Therapeutic potential of targeting TBK1 in autoimmune diseases and interferonopathies

Pharmacological Research

Volumn 111, Issue , 2016, Pages 336-342

  Hasan, Maroof ^a   Yan, Nan ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Autoimmune disease; Interferonopathy; Lupus; TBK1; Type I interferon

Indexed keywords

AMLEXANOX; AZ 13102909; BX 795; COMPOUND II; DOMAINEX; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON; MPI 0485520; MRT 67307; PROTEIN SERINE THREONINE KINASE INHIBITOR; SR 8185; TANK BINDING KINASE 1; UNCLASSIFIED DRUG; IMMUNOLOGIC FACTOR; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; TBK1 PROTEIN, HUMAN;

AUTOIMMUNE DISEASE; CELL MIGRATION; CYTOKINE RESPONSE; DRUG EFFICACY; DRUG POTENCY; DRUG SPECIFICITY; ENZYME ACTIVITY; GENE EXPRESSION; GENETIC DISORDER; HUMAN; INTERFERON INDUCTION; INTERFERONOPATHY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; VIRUS INFECTION; ANIMAL; ANTAGONISTS AND INHIBITORS; AUTOIMMUNITY; DRUG EFFECTS; ENZYMOLOGY; IMMUNOLOGY; METABOLISM; MOLECULARLY TARGETED THERAPY;

ANIMALS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; HUMANS; IMMUNOLOGIC FACTORS; INTERFERONS; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION;

EID: 84979084979     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2016.04.008     Document Type: Review

References (44)

1. [1] Clément, J.-F., Meloche, S., Servant, M.J., The IKK-related kinases: from innate immunity to oncogenesis. Cell Res. 18 (2008), 889–899, 10.1038/cr.2008.273.
2. [2] Kravchenko, V.V., Mathison, J.C., Schwamborn, K., Mercurio, F., Ulevitch, R.J., IKKi/IKKepsilon plays a key role in integrating signals induced by pro-inflammatory stimuli. J. Biol. Chem. 278 (2003), 26612–26619, 10.1074/jbc.M303001200.
3. [3] Bonnard, M., Mirtsos, C., Suzuki, S., Graham, K., Huang, J., Ng, M., et al. 2000, Deficiency of T2 K leads to apoptotic liver degeneration and impaired NF-kappaB-dependent gene transcription. Embo J. 19 (2000), 4976–4985, 10.1093/emboj/19.18.4976.
4. [4] Fitzgerald, K.A., McWhirter, S.M., Faia, K.L., Rowe, D.C., Latz, E., Golenbock, D.T., et al. IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway. Nat. Immunol. 4 (2003), 491–496, 10.1038/ni921.
5. [5] Sharma, S., Tenoever, B.R., Grandvaux, N., Zhou, G.-P., Lin, R., Hiscott, J., Triggering the interferon antiviral response through an IKK-related pathway. Science 300 (2003), 1148–1151, 10.1126/science.1081315.
6. [6] Tamura, T., Yanai, H., Savitsky, D., Taniguchi, T., The IRF family transcription factors in immunity and oncogenesis. Annu. Rev. Immunol. 26 (2008), 535–584, 10.1146/annurev.immunol.26.021607.090400.
7. [7] Weidberg, H., Elazar, Z., TBK1 mediates crosstalk between the innate immune response and autophagy. Sci. Signal., 4, 2011, 10.1126/scisignal.2002355 pe39–pe39.
8. [8] Wild, P., Farhan, H., McEwan, D.G., Wagner, S., Rogov, V.V., Brady, N.R., et al. Phosphorylation of the autophagy receptor optineurin restricts Salmonella growth. Science 333 (2011), 228–233, 10.1126/science.1205405.
9. [9] Thurston, T.L.M., Ryzhakov, G., Bloor, S., von Muhlinen, N., Randow, F., The TBK1 adaptor and autophagy receptor NDP52 restricts the proliferation of ubiquitin-coated bacteria. Nat. Immunol. 10 (2009), 1215–1221, 10.1038/ni.1800.
10. [10] Freischmidt, A., Wieland, T., Richter, B., Ruf, W., Schaeffer, V., Müller, K., et al. Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal dementia. Nat. Neurosci. 18 (2015), 631–636, 10.1038/nn.4000.
11. [11] Chien, Y., Kim, S., Bumeister, R., Loo, Y.-M., Kwon, S.W., Johnson, C.L., et al. RalB GTPase-mediated activation of the IkappaB family kinase TBK1 couples innate immune signaling to tumor cell survival. Cell 127 (2006), 157–170, 10.1016/j.cell.2006.08.034.
12. [12] Ou, Y.-H., Torres, M., Ram, R., Formstecher, E., Roland, C., Cheng, T., et al. TBK1 directly engages Akt/PKB survival signaling to support oncogenic transformation. Mol. Cell 41 (2011), 458–470, 10.1016/j.molcel.2011.01.019.
13. [13] Kim, J.K., Jung, Y., Wang, J., Joseph, J., Mishra, A., Hill, E.E., et al. TBK1 regulates prostate cancer dormancy through mTOR inhibition. Neoplasia 15 (2013), 1064–1074.
14. [14] Shen, R.R., Hahn, W.C., Emerging roles for the non-canonical IKKs in cancer. Oncogene 30 (2011), 631–641, 10.1038/onc.2010.493.
15. [15] Crow, Y.J., Manel, N., Aicardi-Goutières syndrome and the type I interferonopathies. Nat. Rev. Immunol. 15 (2015), 429–440, 10.1038/nri3850.
16. [16] Stetson, D.B., Ko, J.S., Heidmann, T., Medzhitov, R., Trex1 prevents cell-intrinsic initiation of autoimmunity. Cell 134 (2008), 587–598, 10.1016/j.cell.2008.06.032.
17. [17] Hasan, M., Koch, J., Rakheja, D., Pattnaik, A.K., Brugarolas, J., Dozmorov, I., et al. Trex1 regulates lysosomal biogenesis and interferon-independent activation of antiviral genes. Nat. Immunol. 14 (2013), 61–71, 10.1038/ni.2475.
18. [18] Pokatayev, V., Hasin, N., Chon, H., Cerritelli, S.M., Sakhuja, K., Ward, J.M., et al. RNase H2 catalytic core Aicardi-Goutières syndrome-related mutant invokes cGAS-STING innate immune-sensing pathway in mice. J. Exp. Med., 2016, 10.1084/jem.20151464 (jem.20151464).
19. [19] Pestal, K., Funk, C.C., Snyder, J.M., Price, N.D., Treuting, P.M., Stetson, D.B., Isoforms of RNA-Editing enzyme ADAR1 independently control nucleic acid sensor MDA5-Driven autoimmunity and multi-organ development. Immunity 43 (2015), 933–944, 10.1016/j.immuni.2015.11.001.
20. [20] Mannion, N.M., Greenwood, S.M., Young, R., Cox, S., Brindle, J., Read, D., et al. The RNA-editing enzyme ADAR1 controls innate immune responses to RNA. Cell Rep. 9 (2014), 1482–1494, 10.1016/j.celrep.2014.10.041.
21. [21] Gao, D., Li, T., Li, X.-D., Chen, X., Li, Q.-Z., Wight-Carter, M., et al. Activation of cyclic GMP-AMP synthase by self-DNA causes autoimmune diseases. Proc. Natl. Acad. Sci. U. S. A., 1646, 2015, 5, 201516465, 10.1073/pnas.1516465112.
22. [22] Hasan, M., Dobbs, N., Khan, S., White, M.A., Wakeland, E.K., Li, Q.-Z., et al. Cutting edge: inhibiting TBK1 by compound II ameliorates autoimmune disease in mice. J. Immunol., 2015, 10.4049/jimmunol.1500162.
23. [23] Crow, Y.J., Type I interferonopathies: a novel set of inborn errors of immunity. Ann. N. Y. Acad. Sci. 1238 (2011), 91–98, 10.1111/j.1749-6632.2011.06220.x.
24. [24] Becker, A.M., Dao, K.H., Han, B.K., Kornu, R., Lakhanpal, S., Mobley, A.B., et al. SLE peripheral blood B cell, T cell and myeloid cell transcriptomes display unique profiles and each subset contributes to the interferon signature. PLoS One, 8, 2013, e67003, 10.1371/journal.pone.0067003.
25. [25] Crow, M.K., Olferiev, M., Kirou, K.A., Targeting of type I interferon in systemic autoimmune diseases. Transl. Res. 165 (2015), 296–305, 10.1016/j.trsl.2014.10.005.
26. [26] Bennett, L., Palucka, A.K., Arce, E., Cantrell, V., Borvak, J., Banchereau, J., et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J. Exp. Med. 197 (2003), 711–723, 10.1084/jem.20021553.
27. [27] Migita, K., Nakamura, T., TBK1: a potential therapeutic target in RA. Rheumatology (Oxford) 51 (2012), 588–589, 10.1093/rheumatology/ker207.
28. [28] Hammaker, D., Boyle, D.L., Firestein, G.S., Synoviocyte innate immune responses: TANK-binding kinase-1 as a potential therapeutic target in rheumatoid arthritis. Rheumatology (Oxford) 51 (2012), 610–618, 10.1093/rheumatology/ker154.
29. [29] Yu, J., Zhou, X., Chang, M., Nakaya, M., Chang, J.-H., Xiao, Y., et al. Regulation of T-cell activation and migration by the kinase TBK1 during neuroinflammation. Nat. Commun., 6, 2015, 6074, 10.1038/ncomms7074.
30. [30] Wu, T., Xie, C., Han, J., Ye, Y., Weiel, J., Li, Q., et al. Metabolic disturbances associated with systemic lupus erythematosus. PLoS One, 7, 2012, e37210, 10.1371/journal.pone.0037210.
31. [31] Barnerias, C., Giurgea, I., Hertz-Pannier, L., Bahi-Buisson, N., Boddaert, N., Rustin, P., et al. Respiratory chain deficiency in a female with Aicardi-Goutières syndrome. Dev. Med. Child Neurol. 48 (2006), 227–230, 10.1017/S001216220600048X.
32. [32] Haaxma, C.A., Crow, Y.J., van Steensel, M.A.M., Lammens, M.M.Y., Rice, G.I., Verbeek, M.M., et al. A de novo p.Asp18Asn mutation in TREX1 in a patient with Aicardi-Goutières syndrome. Am. J. Med. Genet. A 152A (2010), 2612–2617, 10.1002/ajmg.a.33620.
33. [33] Yu, T., Yang, Y., Yin, D.Q., Hong, S., Son, Y.-J., Kim, J.-H., et al. TBK1 inhibitors: a review of patent literature (2011–2014). Expert Opin. Ther. Pat. 25 (2015), 1385–1396, 10.1517/13543776.2015.1081168.
34. [34] Hasan, M., Fermaintt, C.S., Gao, N., Sakai, T., Miyazaki, T., Jiang, S., et al. Cytosolic nuclease TREX1 regulates oligosaccharyltransferase activity independent of nuclease activity to suppress immune activation. Immunity 43 (2015), 1–13, 10.1016/j.immuni.2015.07.022.
35. [35] Crow, Y.J., Rehwinkel, J., Aicardi-Goutieres syndrome and related phenotypes: linking nucleic acid metabolism with autoimmunity. Hum. Mol. Genet. 18 (2009), R130–6, 10.1093/hmg/ddp293.
36. [36] Christensen, M.H., Paludan, S.R., Viral evasion of DNA-stimulated innate immune responses. Cell. Mol. Immunol., 2016, 10.1038/cmi.2016.06.
37. [37] Wang, T., Block, M.A., Cowen, S., Davies, A.M., Devereaux, E., Gingipalli, L., et al. Discovery of azabenzimidazole derivatives as potent, selective inhibitors of TBK1/IKKε kinases, Bioorg. Med. Chem. Lett. 22 (2012), 2063–2069, 10.1016/j.bmcl.2012.01.018.
38. [38] Vu, H.L., Aplin, A.E., Targeting TBK1 inhibits migration and resistance to MEK inhibitors in mutant NRAS melanoma. Mol. Cancer Res. 12 (2014), 1509–1519, 10.1158/1541-7786.MCR-14-0204.
39. [39] Li, J., Huang, J., Jeong, J.-H., Park, S.-J., Wei, R., Peng, J., et al. Selective TBK1/IKKi dual inhibitors with anticancer potency. Int. J. Cancer 134 (2014), 1972–1980, 10.1002/ijc.28507.
40. [40] Richards, B., Carlson, R., Cellular and in vivo properties of MPI-0485520, a novel and potent small molecule inhibitor of IKKe. FASEB J., 24, 2010 (Supplement 753.6.) http://www.fasebj.org/content/24/1_Supplement/753.6.short.
41. [41] Reilly, S.M., Chiang, S.-H., Decker, S.J., Chang, L., Uhm, M., Larsen, M.J., et al. An inhibitor of the protein kinases TBK1 and IKK-ε improves obesity-related metabolic dysfunctions in mice. Nat. Med., 2013, 10.1038/nm.3082.
42. [42] Mowers, J., Uhm, M., Reilly, S.M., Simon, J., Leto, D., Chiang, S.-H., et al. Inflammation produces catecholamine resistance in obesity via activation of PDE3 B by the protein kinases IKKε and TBK1. Elife, 2, 2013, e01119, 10.7554/eLife.01119.
43. [43] Zhang, Y., Guan, H., Li, J., Fang, Z., Chen, W., Li, F., Amlexanox suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss. Sci. Rep., 5, 2015, 13575, 10.1038/srep13575.
44. [44] Feldman, R.I., Wu, J.M., Polokoff, M.A., Kochanny, M.J., Dinter, H., Zhu, D., et al. Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1. J. Biol. Chem. 280 (2005), 19867–19874, 10.1074/jbc.M501367200.